Welcure Drugs & Pharmaceuticals Limited (WELCURE.BO)
Full history for every metric is available with a Kvantra account
Welcure Drugs & Pharmaceuticals Limited (WELCURE.BO)
No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INR m | 1 | 1 | 1 | 0 | 0 | 246 | 3,655 | 3,655 |
| Operating profit | INR m | -70 | 424 | ||||||
| Net profit | INR m | -0 | 1 | 0 | 1 | -2 | 22 | -55 | -403 |
| EPS reported | INR | -0.04 | 1.75 | ||||||
| Operating cashflow per share | INR | 0.01 | 0.00 | ||||||
| Capex per share | INR | 0.00 | 0.00 | ||||||
| FCF per share | INR | 0.01 | 0.00 | ||||||
| Free cash flow | INR m | 17 | 0 | ||||||
| Net debt | INR m | -6 | -6 | ||||||
| Book value equity | INR m | 970 | 970 | ||||||
| Book value per share | INR | 0.71 | 0.78 | ||||||
| Number of shares | m | 1,372.53 | 1,246.54 | ||||||
| DPS (TTM paid) | INR | 0.00 | 0.00 |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 0.13 | ||||||
| P/B LTM | x | 0.34 | 1.03 | ||||||
| P/S LTM | x | 0.09 | 0.27 | ||||||
| P/FCF LTM | x | 18.98 | 0.00 | ||||||
| EV/EBITDA LTM | x | -4.67 | -30.18 | ||||||
| EV/Sales LTM | x | 0.09 | 0.01 | ||||||
| Earnings Yield LTM | % | -16.67% | +769.23% | ||||||
| FCF Yield | % | +5.27% | 0.00% | ||||||
| Quality | |||||||||
| ROE | % | -5.66% | -34.40% | ||||||
| ROIC | % | -7.17% | -39.69% | ||||||
| Operating margin | % | -1.90% | -10.53% | ||||||
| Gross margin | % | +11.78% | +11.78% | ||||||
| FCF/Sales | % | +0.47% | 0.00% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +1389.0% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.08 | 0.01 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.01 | -0.01 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Welcure Drugs & Pharmaceuticals Ltd., headquartered in New Delhi, India, specializes in the production and distribution of pharmaceutical and medical goods. Dharam Chand Jain founded the company on June 4, 1992.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Welcure Drugs & Pharmaceuticals Limited (WELCURE.BO)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Welcure Drugs & Pharmaceuticals Ltd., headquartered in New Delhi, India, specializes in the production and distribution of pharmaceutical and medical goods. Dharam Chand Jain founded the company on June 4, 1992.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free